NEKTAR THERAPEUTICS's ticker is NKTR and the CUSIP is 640268108. A total of 294 filers reported holding NEKTAR THERAPEUTICS in Q3 2019. The put-call ratio across all filers is 0.81 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2022 | $0 | -100.0% | 34 | -99.3% | 0.00% | -100.0% |
| Q2 2022 | $19,000 | – | 4,946 | +10891.1% | 0.00% | – |
| Q1 2022 | $0 | -100.0% | 45 | -40.0% | 0.00% | – |
| Q4 2021 | $1,000 | -94.1% | 75 | -91.9% | 0.00% | -100.0% |
| Q3 2021 | $17,000 | -19.0% | 926 | -25.7% | 0.00% | 0.0% |
| Q2 2021 | $21,000 | +16.7% | 1,247 | +34.8% | 0.00% | 0.0% |
| Q1 2021 | $18,000 | -50.0% | 925 | -55.5% | 0.00% | 0.0% |
| Q4 2020 | $36,000 | +200.0% | 2,080 | +186.5% | 0.00% | +33.3% |
| Q3 2020 | $12,000 | +71.4% | 726 | +132.7% | 0.00% | +50.0% |
| Q2 2020 | $7,000 | – | 312 | +1460.0% | 0.00% | – |
| Q1 2020 | $0 | – | 20 | +150.0% | 0.00% | – |
| Q2 2019 | $0 | – | 8 | +14.3% | 0.00% | – |
| Q4 2018 | $0 | – | 7 | +40.0% | 0.00% | – |
| Q2 2018 | $0 | -100.0% | 5 | 0.0% | 0.00% | -100.0% |
| Q1 2018 | $1,000 | – | 5 | 0.0% | 0.00% | – |
| Q4 2017 | $0 | – | 5 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Camber Capital Management LP | 2,000,000 | $67,200,000 | 3.35% |
| First Light Asset Management, LLC | 763,403 | $25,650,000 | 3.33% |
| BRIDGER MANAGEMENT, LLC | 1,238,489 | $41,613,000 | 3.29% |
| Rhenman & Partners Asset Management AB | 734,445 | $24,677,000 | 2.89% |
| BB BIOTECH AG | 2,020,676 | $67,895,000 | 1.71% |
| Gs Investments, Inc. | 54,200 | $1,821,120,000 | 1.43% |
| Artal Group S.A. | 900,000 | $30,240,000 | 1.24% |
| Cormorant Asset Management, LP | 500,000 | $16,800,000 | 1.14% |
| TOBAM | 640,547 | $21,522,000 | 1.09% |
| Bellevue Group AG | 430,026 | $14,449,000 | 0.80% |